Dianthus Therapeutics Raises $719M in Upsized Offering

Fairmount Funds Management LLC Increases Stake to Become Largest Shareholder

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has raised $719 million in an upsized underwritten public offering, strengthening the company's cash runway for its clinical development programs. The offering was well-received, with Fairmount Funds Management LLC increasing its stake in the company to become the largest shareholder, owning 7.71% of Dianthus Therapeutics.

Why it matters

The successful capital raise and Fairmount Funds' increased investment demonstrate strong investor confidence in Dianthus Therapeutics' pipeline and future prospects. The additional funding will allow the company to advance its lead candidate, DNTH103, which is currently in Phase 2 clinical trials for the treatment of autoimmune and inflammatory disorders.

The details

Dianthus Therapeutics completed the upsized underwritten public offering, generating approximately $719 million in gross proceeds, including the full exercise of the underwriters' option. The company plans to use the funds to support the ongoing development of DNTH103 and for general corporate purposes.

  • Dianthus Therapeutics announced the closing of the upsized offering on 2026-03-16.
  • Fairmount Funds Management LLC increased its stake in Dianthus Therapeutics by 22.2% in the third quarter of 2025.

The players

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Fairmount Funds Management LLC

An investment management firm that has become the largest shareholder of Dianthus Therapeutics, owning 7.71% of the company's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The additional funding from the upsized offering will allow Dianthus Therapeutics to accelerate the development of DNTH103 and potentially expand its pipeline of complement-targeted therapies.

The takeaway

Dianthus Therapeutics' successful capital raise and the increased investment from Fairmount Funds Management LLC demonstrate the strong investor confidence in the company's potential to address unmet needs in autoimmune and inflammatory diseases. The additional funding will support the advancement of the company's clinical programs and strengthen its position as a leader in the complement therapeutics space.